These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6251193)

  • 21. Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate.
    Weinstock RS; Moses AM
    South Med J; 1990 Dec; 83(12):1475-7. PubMed ID: 2123565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diabetes insipidus in infancy and childhood].
    Sólyom J; Bognár I; Mátyus J
    Orv Hetil; 1981 May; 122(19):1125-8. PubMed ID: 7267106
    [No Abstract]   [Full Text] [Related]  

  • 23. Desamino-D-Arginine vasopressin induces fatty acid cyclooxygenase activity in the renal medulla of diabetes insipidus rats.
    Beck TR; Hassid A; Dunn MJ
    J Pharmacol Exp Ther; 1982 May; 221(2):269-74. PubMed ID: 6804621
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of vasopressin-sensitive diabetes insipidus in children with DDAVP].
    Gerards LJ; van Leeuwen EF; Donckerwolcke RA; Kuijten RH
    Ned Tijdschr Geneeskd; 1975 Aug; 119(33):1269-72. PubMed ID: 1165795
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus.
    Vierhapper H; Jörg J; Favre L; Vallotton MB; Waldhäusl W
    Acta Endocrinol (Copenh); 1984 Jul; 106(3):311-6. PubMed ID: 6588700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin.
    Lum GM; Aisenbrey GA; Dunn MJ; Berl T; Schrier RW; McDonald KM
    J Clin Invest; 1977 Jan; 59(1):8-13. PubMed ID: 187624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laurence-Moon-Biedl syndrome associated with diabetes insipidus neurohormonalis.
    Koepp P
    Eur J Pediatr; 1975 Dec; 121(1):59-62. PubMed ID: 1213037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
    Bichet DG; Razi M; Lonergan M; Arthus MF; Papukna V; Kortas C; Barjon JN
    N Engl J Med; 1988 Apr; 318(14):881-7. PubMed ID: 2965301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postcraniotomy diabetes insipidus: treatment with DDAVP, a synthetic analog of vasopressin.
    Daneman D; Ehrlich RM; Bailey JD
    J Pediatr; 1978 Nov; 93(5):879-80. PubMed ID: 712500
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of the prostaglandin system in the regulation of renal function in normal women.
    Güllner HG; Gill JR; Bartter FC; Düsing R
    Am J Med; 1980 Nov; 69(5):718-24. PubMed ID: 6254359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of aprotinin on the renal response to vasopressin in diabetes insipidus rats.
    Fejes-Toth G; Frölich JC; Naray-Fejes-Toth A
    J Physiol; 1983 Jun; 339():585-90. PubMed ID: 6193269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic diabetes insipidus: clinical and pathophysiological aspects.
    Niaudet P; Dechaux M; Trivin C; Loirat C; Broyer M
    Adv Nephrol Necker Hosp; 1984; 13():247-60. PubMed ID: 6089520
    [No Abstract]   [Full Text] [Related]  

  • 33. Basal and hormone-induced urinary cyclic AMP in children with renal disorders.
    Monn E; Osnes JB; Oye I
    Acta Paediatr Scand; 1976 Nov; 65(6):739-45. PubMed ID: 187004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes insipidus: clinical and basic aspects.
    Majzoub JA; Srivatsa A
    Pediatr Endocrinol Rev; 2006 Dec; 4 Suppl 1():60-5. PubMed ID: 17261971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of vasopressin on prostaglandin excretion in conscious dogs.
    Fejes-Tóth G; Filep J; Mann V
    J Physiol; 1983 Nov; 344():389-97. PubMed ID: 6361236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Congenital nephrogenic diabetes insipidus in a baby girl.
    Schreiner RL; Skafish PR; Anand SK; Northway JD
    Arch Dis Child; 1978 Nov; 53(11):906-8. PubMed ID: 215090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria.
    Sugawara M; Hashimoto K; Ota Z
    Am J Physiol; 1988 Jun; 254(6 Pt 2):R863-9. PubMed ID: 2454589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of urinary prostaglandin E and cyclic AMP in the polyuria of hypokalemia in rats.
    Gullner HG; Bartter FC
    Prostaglandins Med; 1980 Jan; 4(1):13-9. PubMed ID: 6247732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of inhibition of prostaglandin synthesis on free water and osmolar clearances in patients with hereditary nephrogenic diabetes insipidus.
    Blachar Y; Zadik Z; Shemesh M; Kaplan BS; Levin S
    Int J Pediatr Nephrol; 1980 Mar; 1(1):48-52. PubMed ID: 7343530
    [No Abstract]   [Full Text] [Related]  

  • 40. [Inhibition of prostaglandin synthesis during the therapy of nephrogenic diabetes insipidus].
    Stögmann W; Bohrn E
    Wien Klin Wochenschr; 1984 Jan; 96(1):12-6. PubMed ID: 6710993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.